RxDoctor Payments Data

Vanitha Bala, MD

Gastroenterology · Shenandoah, TXNPI 1386662351

Payments from drug & device makers

$7,192in general payments, 2019–2025

Across 215 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$920
  • QOL Medical, LLC$773
  • Phathom Pharmaceuticals, Inc.$513
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
  • Novo Nordisk$377
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$7,15099%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,192 in reported general payments places this provider in the 65th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$134,977
Medicare patients
373
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide68$52,346
VoqueznaVonoprazan Fumarate12$9,933
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates148$9,405
Dexlansoprazole DrDexlansoprazole18$7,801
Mesalamine19$7,393
Pantoprazole Sodium381$4,395
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,433
Cholestyramine LightCholestyramine31$3,171
PrevaliteCholestyramine16$2,900
CholestyramineCholestyramine (With Sugar)22$2,581
Sucralfate85$1,827
Omeprazole148$1,665
Famotidine138$1,625
Dicyclomine Hcl80$1,222
Esomeprazole Magnesium23$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,402$52,34668 claims
Phathom Pharmaceuticals, Inc.Voquezna$513$9,93312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →